{"id":177888,"date":"2026-07-31T10:01:52","date_gmt":"2026-07-31T04:31:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=177888"},"modified":"2026-07-31T10:01:53","modified_gmt":"2026-07-31T04:31:53","slug":"alivus-life-sciences-q1-results-fy27-pat-rs-160-cr","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/","title":{"rendered":"Alivus Life Sciences Q1 Results FY27: Net Profit at Rs 160 Cr for June 2026 Quarter"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Alivus Life Sciences Q1 results FY27: Revenue Rs 640 Cr. Net profit Rs 160 Cr. Standalone basis. Stock at Rs 1,096 (-2.13%) on 30 July 2026.<\/em><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Key_Takeaways\" title=\"Key Takeaways\">Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Alivus_Life_Sciences_Q1_Results_FY27_Key_Numbers_at_a_Glance\" title=\"Alivus Life Sciences Q1 Results FY27: Key Numbers at a Glance\">Alivus Life Sciences Q1 Results FY27: Key Numbers at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Alivus_Life_Sciences_Q1_Results_FY27_What_Drove_Revenue\" title=\"Alivus Life Sciences Q1 Results FY27: What Drove Revenue\">Alivus Life Sciences Q1 Results FY27: What Drove Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Alivus_Life_Sciences_Q1_Results_FY27_Profitability_Breakdown\" title=\"Alivus Life Sciences Q1 Results FY27: Profitability Breakdown\">Alivus Life Sciences Q1 Results FY27: Profitability Breakdown<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Stock_Price_Reaction_to_the_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"Stock Price Reaction to the Alivus Life Sciences Q1 Results FY27\">Stock Price Reaction to the Alivus Life Sciences Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#What_the_Alivus_Life_Sciences_Q1_Results_FY27_Mean_for_Investors\" title=\"What the Alivus Life Sciences Q1 Results FY27 Mean for Investors\">What the Alivus Life Sciences Q1 Results FY27 Mean for Investors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Business_Context_Behind_the_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"Business Context Behind the Alivus Life Sciences Q1 Results FY27\">Business Context Behind the Alivus Life Sciences Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Key_Things_to_Watch_After_the_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"Key Things to Watch After the Alivus Life Sciences Q1 Results FY27\">Key Things to Watch After the Alivus Life Sciences Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#FAQs_on_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"FAQs on Alivus Life Sciences Q1 Results FY27\">FAQs on Alivus Life Sciences Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#What_was_Alivus_Life_Sciencess_revenue_in_Q1_results_FY27\" title=\"What was Alivus Life Sciences&#8217;s revenue in Q1 results FY27?\">What was Alivus Life Sciences&#8217;s revenue in Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Did_Alivus_Life_Sciences_make_a_profit_or_loss_in_Q1_FY27\" title=\"Did Alivus Life Sciences make a profit or loss in Q1 FY27?\">Did Alivus Life Sciences make a profit or loss in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#What_was_Alivus_Life_Sciencess_gross_profit_in_Q1_FY27\" title=\"What was Alivus Life Sciences&#8217;s gross profit in Q1 FY27?\">What was Alivus Life Sciences&#8217;s gross profit in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#When_were_the_Alivus_Life_Sciences_Q1_results_FY27_announced\" title=\"When were the Alivus Life Sciences Q1 results FY27 announced?\">When were the Alivus Life Sciences Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Did_Alivus_Life_Sciences_shares_go_up_or_down_after_the_Q1_results_FY27\" title=\"Did Alivus Life Sciences shares go up or down after the Q1 results FY27?\">Did Alivus Life Sciences shares go up or down after the Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Were_the_Alivus_Life_Sciences_Q1_results_FY27_consolidated_or_standalone\" title=\"Were the Alivus Life Sciences Q1 results FY27 consolidated or standalone?\">Were the Alivus Life Sciences Q1 results FY27 consolidated or standalone?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#What_should_investors_watch_after_Alivus_Life_Sciencess_Q1_results_FY27\" title=\"What should investors watch after Alivus Life Sciences&#8217;s Q1 results FY27?\">What should investors watch after Alivus Life Sciences&#8217;s Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr\/#Are_the_Alivus_Life_Sciences_Q1_results_FY27_a_buy_signal\" title=\"Are the Alivus Life Sciences Q1 results FY27 a buy signal?\">Are the Alivus Life Sciences Q1 results FY27 a buy signal?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Takeaways\"><\/span><strong>Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Alivus Life Sciences&#8217;s revenue for the June 2026 quarter came in at Rs 640 Cr, rose 6.41% year on year from Rs 601 Cr.<\/li>\n<li>Alivus Life Sciences came in at a standalone net profit of Rs 160 Cr, up 31.71% from Rs 121 Cr in Q1 FY26.<\/li>\n<li>Gross profit was reported at Rs 191 Cr for the quarter.<\/li>\n<li>The stock traded at Rs 1,096 on 30 July 2026, down 2.13% during the session.<\/li>\n<\/ul>\n<p>If you are searching for Alivus Life Sciences Q1 results FY27, here is the direct answer: Alivus Life Sciences reported standalone revenue of Rs 640 Cr and a net profit of Rs 160 Cr for the quarter ended 30 June 2026, rose 6.41% year on year from Rs 601 Cr. The rest of this article expands on that answer with the full revenue and profit breakdown, what changed compared with Q1 FY26, how the stock reacted, and what to watch next, so you do not need to piece it together from multiple sources.<\/p>\n<p>Prepared by Ankit Jaiswal, Senior Research Analyst at Univest, this review of the Alivus Life Sciences Q1 results FY27 is based on figures disclosed in the company&#8217;s exchange filing for the June 2026 quarter.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=alivus-life-sciences-q1-results-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q1_Results_FY27_Key_Numbers_at_a_Glance\"><\/span><strong>Alivus Life Sciences Q1 Results FY27: Key Numbers at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr style=\"background: #EBF3FB;\">\n<th>Metric<\/th>\n<th>Q1 FY27<\/th>\n<th>Q1 FY26<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td style=\"text-align: right;\">Rs 640 Cr<\/td>\n<td style=\"text-align: right;\">Rs 601 Cr<\/td>\n<td style=\"text-align: right;\">6.41%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td style=\"text-align: right;\">Rs 191 Cr<\/td>\n<td style=\"text-align: right;\">Rs 155 Cr<\/td>\n<td style=\"text-align: right;\">23.11%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit<\/td>\n<td style=\"text-align: right;\">Rs 160 Cr<\/td>\n<td style=\"text-align: right;\">Rs 121 Cr<\/td>\n<td style=\"text-align: right;\">31.71%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All figures in the Alivus Life Sciences Q1 results FY27 table above are on a standalone basis for the quarter ended 30 June 2026, compared with Q1 FY26. This is the core data set behind the Alivus Life Sciences Q1 results FY27 search.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q1_Results_FY27_What_Drove_Revenue\"><\/span><strong>Alivus Life Sciences Q1 Results FY27: What Drove Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Revenue for <a href=\"https:\/\/univest.in\/stocks\/alivus\/glenmark-life-sciences-ltd-share-price-today\">Alivus Life Sciences<\/a> in Q1 FY27 rose 6.41% from Rs 601 Cr to Rs 640 Cr, against Rs 601 Cr in Q1 FY26. Anyone comparing Alivus Life Sciences against its own past performance should treat this as the base number: a company in the pharmaceutical API manufacturing space, this pace of growth reflects demand and pricing trends specific to that segment during the June 2026 quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q1_Results_FY27_Profitability_Breakdown\"><\/span><strong>Alivus Life Sciences Q1 Results FY27: Profitability Breakdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences came in at a standalone net profit of Rs 160 Cr, up 31.71% from Rs 121 Cr in Q1 FY26 in Q1 FY27. Gross profit for the quarter was Rs 191 Cr, a change of 23.11% from Rs 155 Cr in Q1 FY26.<\/p>\n<p>The broadly consistent movement between gross profit and net profit in the Alivus Life Sciences Q1 results FY27 suggests the quarter&#8217;s profit performance is being driven mainly by core operations rather than one-off or below-the-line items.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Stock_Price_Reaction_to_the_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>Stock Price Reaction to the Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences shares traded at Rs 1,096 on 30 July 2026, down 2.13% during the session. If your search intent is specifically about the stock reaction rather than the raw numbers, this is the figure that answers it: the market&#8217;s verdict weighed the revenue and profit results together, alongside broader market conditions on the day.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Talk to a SEBI Registered Investment Adviser Before You Invest<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_the_Alivus_Life_Sciences_Q1_Results_FY27_Mean_for_Investors\"><\/span><strong>What the Alivus Life Sciences Q1 Results FY27 Mean for Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alivus Life Sciences Q1 results FY27 give investors three concrete data points: a revenue base of Rs 640 Cr, a net profit of Rs 160 Cr, and a year-on-year growth trajectory that either confirms or challenges the investment thesis for the stock. None of these numbers should be read in isolation from the detailed exchange filing, segment disclosures and management commentary that typically accompany results.<\/p>\n<p>Comparing this quarter with peers in the pharmaceutical API manufacturing space is also useful context. A company can post strong absolute growth and still lag its peer set, or post modest growth that is nonetheless best-in-class for its sector, so relative positioning matters as much as the standalone numbers in the Alivus Life Sciences Q1 results FY27. Investors who track a basket of names in the same industry will typically get a clearer read on whether this quarter reflects a company-specific story or a broader sector trend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Business_Context_Behind_the_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>Business Context Behind the Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences operates in the pharmaceutical API manufacturing space, where demand cycles, input costs and competitive intensity all shape quarterly performance. The Alivus Life Sciences Q1 results FY27 should be read against these sector-level dynamics rather than as a standalone number, since the same growth rate can carry very different implications depending on the underlying industry conditions.<\/p>\n<p>Quarterly results are unaudited and subject to limited review, so any restatements or exceptional items disclosed in the notes to the Alivus Life Sciences Q1 results FY27 can shift how the reported profit should be interpreted. Reading the full exchange filing alongside this summary remains the most reliable way to form a complete view, particularly for line items such as other income, exceptional items and tax adjustments that do not always show up in a headline summary.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Things_to_Watch_After_the_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>Key Things to Watch After the Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Sequential trend:<\/strong> Whether the momentum in the Alivus Life Sciences Q1 results FY27 carries into the September 2026 quarter or proves to be a one-off.<\/li>\n<li><strong>Management commentary:<\/strong> Guidance on demand, margins and capital allocation for the rest of FY27.<\/li>\n<li><strong>Sector conditions:<\/strong> Developments in the pharmaceutical API manufacturing space that could influence input costs, pricing power or competitive intensity.<\/li>\n<li><strong>Corporate actions:<\/strong> Any dividend, capex or strategic announcements accompanying the results that signal management&#8217;s confidence in the outlook.<\/li>\n<li><strong>Balance sheet health:<\/strong> Debt levels, working capital trends and cash flow generation, which together determine how much flexibility Alivus Life Sciences has to fund future growth.<\/li>\n<\/ul>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track quarterly results, live prices and research updates in one place.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alivus Life Sciences Q1 results FY27 show standalone revenue of Rs 640 Cr and a net profit of Rs 160 Cr for the quarter ended 30 June 2026. The quarter&#8217;s profit delivery keeps the near-term earnings narrative broadly intact. As Ankit Jaiswal notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these results.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 14px 18px; margin-top: 24px;\">\n<p style=\"color: #ffffff; margin: 0;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and should not be considered investment advice. Revenue, gross profit and net profit figures are sourced from the company&#8217;s exchange filings for the quarter ended 30 June 2026. Stock market investments are subject to risks. Please consult a SEBI registered investment adviser before making any investment decision. Univest Research Analyst SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>FAQs on Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Alivus_Life_Sciencess_revenue_in_Q1_results_FY27\"><\/span><strong>What was Alivus Life Sciences&#8217;s revenue in Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences&#8217;s revenue in Q1 results FY27 was Rs 640 Cr, rose 6.41% year on year from Rs 601 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Alivus_Life_Sciences_make_a_profit_or_loss_in_Q1_FY27\"><\/span><strong>Did Alivus Life Sciences make a profit or loss in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences reported a net profit of Rs 160 Cr in Q1 results FY27 on a standalone basis for the quarter ended 30 June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Alivus_Life_Sciencess_gross_profit_in_Q1_FY27\"><\/span><strong>What was Alivus Life Sciences&#8217;s gross profit in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences&#8217;s gross profit in Q1 results FY27 was Rs 191 Cr, against Rs 155 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Alivus_Life_Sciences_Q1_results_FY27_announced\"><\/span><strong>When were the Alivus Life Sciences Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alivus Life Sciences Q1 results FY27 were announced on 30 July 2026, covering the quarter ended 30 June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Alivus_Life_Sciences_shares_go_up_or_down_after_the_Q1_results_FY27\"><\/span><strong>Did Alivus Life Sciences shares go up or down after the Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences shares traded at Rs 1,096 on 30 July 2026, down 2.13% following the Q1 results FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Were_the_Alivus_Life_Sciences_Q1_results_FY27_consolidated_or_standalone\"><\/span><strong>Were the Alivus Life Sciences Q1 results FY27 consolidated or standalone?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alivus Life Sciences Q1 results FY27 are on a standalone basis, as reported in the company&#8217;s exchange filing for the June 2026 quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_watch_after_Alivus_Life_Sciencess_Q1_results_FY27\"><\/span><strong>What should investors watch after Alivus Life Sciences&#8217;s Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should watch the sequential trend into the September quarter, management commentary, sector-level conditions in the pharmaceutical API manufacturing space, and any corporate action announcements.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_the_Alivus_Life_Sciences_Q1_results_FY27_a_buy_signal\"><\/span><strong>Are the Alivus Life Sciences Q1 results FY27 a buy signal?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alivus Life Sciences Q1 results FY27: standalone net profit at Rs 160 Cr and revenue at Rs 640 Cr for the quarter ended June 2026. Direct answer plus full breakdown in&#8230;<\/p>\n","protected":false},"author":34,"featured_media":177880,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3841],"tags":[3802],"class_list":["post-177888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mutual-funds","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["177880"],"_edit_lock":["1785472316:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["3841"],"rank_math_seo_score":["76"],"rank_math_title":["Alivus Life Sciences Q1 Results FY27: PAT Rs 160 Cr Reported"],"rank_math_description":["Alivus Life Sciences Q1 results FY27: standalone net profit at Rs 160 Cr and revenue at Rs 640 Cr for the quarter ended June 2026. Direct answer plus full breakdown"],"rank_math_focus_keyword":["Alivus Life Sciences Q1 results FY27"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["32270"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/alivus-life-sciences-q1-results-fy27-pat-rs-160-cr.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/177888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=177888"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/177888\/revisions"}],"predecessor-version":[{"id":178108,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/177888\/revisions\/178108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/177880"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=177888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=177888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=177888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}